Krishnansu S. Tewari, MD, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.
Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California Irvine in Orange, California, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.
Patients with recurrent cervical cancer have few therapeutic options, Tewari notes. To help alleviate this, this trial compared a regimen of chemotherapy alone to chemotherapy plus bevacizumab and found an increase in overall survival of 3.7 months. Additionally, the side effect profile for the combination was consistent with expectations for bevacizumab as a monotherapy.
<<<
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More